Yukiko Sato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yukiko Sato has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Akitaka Tsujikawa
Department of Ophthalmology and Visual Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan
2 shared publications - Atsushi Takahashi
Kibi International University
2 shared publications Chikako Hara
Department of Ophthalmology, Graduate School of Medicine, Osaka University, Osaka, Japan
2 shared publicationsHajime Takahashi
Department of Ophthalmology, Kansai Medical University, Hirakata, Osaka, Japan
2 shared publications- Hideki Koizumi
Department of Ophthalmology, Graduate School of Medicine, University of the Ryukyus, Okinawa, Japan
2 shared publications Kanji Takahashi
Department of Ophthalmology, Kansai Medical University, Hirakata, Osaka, Japan
2 shared publications
Latest Publications
- Open Access
- 10 April 2024
- Published by Elsevier in Ophthalmology Science
- Vol. 4 (5) , 100528
Clinical Characteristics and Progression of Pachychoroid and Conventional Geographic Atrophy
- 10 April 2024
- Published by Elsevier in Ophthalmology Science
- Vol. 4 (5) , 100528
Open AccessClinical Characteristics and Progression of Pachychoroid and Conventional Geographic Atrophy
- Open Access
- 10 June 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 7 (10) , 901-909
Clinical Characteristics and Progression of Geographic Atrophy in a Japanese Population
- 10 June 2023
- Published by Elsevier in Ophthalmology Retina
- Vol. 7 (10) , 901-909
Open AccessClinical Characteristics and Progression of Geographic Atrophy in a Japanese Population
- Open Access
- 7 March 2022
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 135 (5)
Lipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs
Membrane proteins often cluster in nanoscale membrane domains (lipid rafts) that coalesce into ceramide-rich platforms during cell stress, however the clustering mechanisms remain uncertain. The cystic fibrosis transmembrane conductance regulator (CFTR), which is mutated in cystic fibrosis (CF), forms clusters that are cholesterol dependent and become incorporated into long-lived platforms during hormonal stimulation. We report here that clustering does not involve known tethering interactions of CFTR with PDZ domain proteins, filamin A or the actin cytoskeleton. It also does not require CFTR palmitoylation but is critically dependent on membrane lipid order and is induced by detergents that increase the phase separation of membrane lipids. Clustering and integration of CFTR into ceramide-rich platforms are abolished by the disease mutations F508del and S13F and rescued by the CFTR modulators elexacaftor plus tezacaftor. These results indicate CF therapeutics that correct mutant protein folding restore both trafficking and normal lipid interactions in the plasma membrane. This article has an associated First Person interview with the first author of the paper.
- 7 March 2022
- Published by The Company of Biologists in Journal of Cell Science
- Vol. 135 (5)
Open AccessLipid-driven CFTR clustering is impaired in cystic fibrosis and restored by corrector drugs
Membrane proteins often cluster in nanoscale membrane domains (lipid rafts) that coalesce into ceramide-rich platforms during cell stress, however the clustering mechanisms remain uncertain. The cystic fibrosis transmembrane conductance regulator (CFTR), which is mutated in cystic fibrosis (CF), forms clusters that are cholesterol dependent and become incorporated into long-lived platforms during hormonal stimulation. We report here that clustering does not involve known tethering interactions of CFTR with PDZ domain proteins, filamin A or the actin cytoskeleton. It also does not require CFTR palmitoylation but is critically dependent on membrane lipid order and is induced by detergents that increase the phase separation of membrane lipids. Clustering and integration of CFTR into ceramide-rich platforms are abolished by the disease mutations F508del and S13F and rescued by the CFTR modulators elexacaftor plus tezacaftor. These results indicate CF therapeutics that correct mutant protein folding restore both trafficking and normal lipid interactions in the plasma membrane. This article has an associated First Person interview with the first author of the paper.